Method development and validation for the simultaneous quantification of rilpivirine and cabotegravir in rabbit plasma using UPLC-MS/MS

A new UPLC-MS/MS method has been developed for the simultaneous estimation of Rilpivirine and Cabotegravir in rabbit plasma and the method was validated. Cabotegravir and Rilpivirine are anti-viral drugs. The combination of Cabotegravir and Rilpivirine is used to inhibit the reproduction of the HIV-1 virus and it is available as long-acting injectable formulation. Agilent Eclipse Phenyl XDB column was employed for the study and a mixture of Acetonitrile and 2 mM Ammonium formate with 0.1% formic acid (40: 60) was used as mobile phase with flow rate 0.8 mL/min.